HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer.

A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 10 October 2026).

A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.